WAVE Life Sciences Ltd.
WVE
$6.73
-$0.06-0.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -4.42% | -37.29% | 202.25% | 661.49% | 3,005.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.42% | -37.29% | 202.25% | 661.49% | 3,005.10% |
| Cost of Revenue | 22.82% | 17.40% | 13.51% | 10.98% | 12.22% |
| Gross Profit | -207.59% | -129.98% | 66.37% | 81.29% | 85.11% |
| SG&A Expenses | 15.07% | 10.12% | 9.64% | 4.43% | 1.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.63% | 15.30% | 12.39% | 9.04% | 8.98% |
| Operating Income | -62.37% | -63.71% | 38.56% | 53.41% | 58.21% |
| Income Before Tax | -66.71% | -67.74% | 43.19% | 58.64% | 63.89% |
| Income Tax Expenses | -- | -100.00% | -199.41% | -199.41% | -199.41% |
| Earnings from Continuing Operations | -68.67% | -67.73% | 44.00% | 59.27% | 64.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.67% | -67.73% | 44.00% | 59.27% | 64.46% |
| EBIT | -62.37% | -63.71% | 38.56% | 53.41% | 58.21% |
| EBITDA | -69.07% | -69.23% | 39.11% | 54.55% | 59.66% |
| EPS Basic | -42.17% | -28.24% | 56.96% | 70.26% | 74.09% |
| Normalized Basic EPS | -41.18% | -28.75% | 56.43% | 69.90% | 73.81% |
| EPS Diluted | -43.46% | -29.22% | 56.77% | 70.08% | 73.94% |
| Normalized Diluted EPS | -43.06% | -28.65% | 56.38% | 69.86% | 73.78% |
| Average Basic Shares Outstanding | 30.64% | 22.93% | 19.99% | 26.36% | 34.39% |
| Average Diluted Shares Outstanding | 32.90% | 22.64% | 20.23% | 26.63% | 34.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |